Baar, July 12, 2022 – PolyPeptide Group AG ^
PolyPeptide Group / Keywords: Semi-Annual Results / Profit Drop
The PolyPeptide group announced the course of its activity
12/07/2022 / 07:00 CET / CEST
The best jobs of the day
Find the best job offers now and
be notified by e-mail.
Publication of an ad hoc advertisement in accordance with Art. 53 LR
The issuer / publisher is responsible for the content of the application.
————————————————– —————————————
Publication for the media – Ad hoc publication pursuant to Art. 53 of the CoR
PolyPeptide informed about the course of business
Baar, July 12, 2022 – PolyPeptide Group AG (PolyPeptide), global
a leading contract developer and producer of peptides and
Oligonucleotides, informed about the course of the activity. during this
The company continues the implementation of its development strategy
invested, expects a lower profit in the first half of 2022.
compared to the first half of 2021. EBITDA margin for the first half of the year
Mid-2022 is expected to account for around 20% of sales.
Development comes from a combination of factors. Down
firstly, sales in the first half of 2022 will be approximately at the level
the same period last year, but the business mix was exceptional then
cheap. In addition, PolyPeptide was able to increase the cost of raw materials,
We are not yet handing over energy, consumables and wages to our customers.
Finally, PolyPeptide has an organization to grow
further expansion of the business and the average number
employees (full-time equivalents) compared to June 2021 via
Increase of approximately 13% in all production sites.
Moreover, PolyPeptide is looking forward to the current development
The coronavirus pandemic has postponed part of the schedule to 2022.
Pending sales related to COVID-19 by 2023 PolyPeptide will be
further details on the results for the first half of 2022 i
Outlook update for the financial year 2022, scheduled for April 19
Planned semi-annual report for August 2022.
PolyPeptide focuses on a strategic growth program to …
long-term potential for core activities with peptides and oligonucleotides
realize. On the one hand, the company invests in the other
Extending the possibilities of handling customer projects in the clinical phase III
Development. On the other hand, it strives for constant expansion
its funnel, with a backlog of 181 active customer projects at the end
June 2021 may be increased to 218 projects by the end of June 2022.
contact
PolyPeptide Group AG
Michael Stäheli, director of investor relations and corporate communications
[email protected]+41 41 723 20 34
About Polypeptide
PolyPeptide is a contract developer and manufacturer (CDMO) in the field
Proprietary and generic GMP grade peptides manufactured by the pharmaceutical company i
Biotech company in approved pharmaceutical products, drugs
in clinical development and generics. This
The company, which dates back to 1952, today makes approx
half of all currently approved peptide active ingredients and has
global reach with six GMP-certified manufacturing sites in
Europe, USA and India. As an international company with around 1100
employees by the end of 2021 PolyPeptide combines comprehensive knowledge and
Experience. PolyPeptide is organic and through selective acquisitions
existing knowledge and is currently a leading company in
peptide production outsourcing. PolyPeptide Shares (SIX: PPGN)
are listed on the SIX Swiss Exchange. For more information, see
on the website polieptyd.com.
@PolyPeptide – Follow us on LinkedIn
Forward-Looking Information Notice
This press release was prepared and includes PolyPeptide Group AG
forward-looking information and statements
Group business prospects. These statements are based on the current statements
Expectations, estimates and forecasts about the factors that
may affect the company’s future results. This
Generally, expectations, estimates and projections are related to the statements
recognize words such as “expect”, “believe”, “evaluate”, “aim”,
“Plan”, “perspective” or similar expressions. There are many of them
Risks, uncertainties, and other factors, many of which are beyond
are under the control of PolyPeptide Group AG, which may result in:
the actual results of the group differ significantly from those on this one
the press release contained information and forward-looking statements
vary, which can affect the group’s ability to:
achieve the set goals. Among the important factors leading to such
Deviations may include, but are not limited to: Relationships with
employees, customers and other business partners; strategies
competitors; production capacity and use; quality defects;
supply chain matters; legal, tax or
regulatory disputes; and changes in policy
the social and regulatory environment in which the Group operates,
or relating to economic or technological development or
Conditions. Although PolyPeptide Group AG assumes that their
Expectations reflected in such forward-looking statements
based on reasonable assumptions, cannot guarantee that
these expectations are actually met.
Alternative Financial Performance Measures (APM)
This press release contains references to operational indicators,
for example, active customer projects and APMs that are not covered by IFRS
are defined or determined, including EBITDA. They should be like
supplementary information to the group’s consolidated financial results
based on IFRS and not as a substitute for it. She
may not match similarly named other people’s metrics
comparable companies. Agent definitions
You can find pointers and APMs, including relevant shortcuts
in the “Definitions and arrangements” section of the 2021 Annual Report and
Bi-annual report 2022 (once published) by PolyPeptide Group AG.
————————————————– —————————————
End of ad hoc announcement
————————————————– —————————————
German
Company: PolyPeptide Group
Neuhofstraße 24
6340 Baars
Switzerland
Telephone: +41 417 232 040
E-mail: [email protected]
Web: www.polipeptide.com
ISIN: CH1110760852
Security number: 111076085
Exchanges: SIX Swiss Exchange
EQS message ID: 1395563
End of news EQS news service
————————————————– —————————————
1395563 07/12/2022 CET / CEST
°